Company: Barrington James Scientific
Location: Belgium, Nerherlands
Reference: cs science
Closing Date: 19 Apr 17
Type: Full Time
Salary (£): Competitive
We have an exciting opportunity available as a Group Leader of Biomarker and Translational Medicine at an exciting biotech based in Belgium. This is a fantastic opportunity for an experienced scientific professional to enter into a strategic senior position with project design and implementation responsibility.
Extensive experience with Biomarkers (discovery, characterization, clinical validation etc.)
Experience in Immunology and/or Oncology
PHD in Cancer Biology or similar
Experience in validation, development, and outsourcing biomarker assays
Leading the translational sciences- biomarker group
Lead the development and implementation of biomarker and diagnostic project strategies
Manage the validation, development and outsourcing of clinically applicable biomarker assays
Oversight of pharmacodynamic and patient selection for biomarker, diagnostic testing and complex data analysis
Participating in experimental work to assist biomarker assay development and/or validation
This is a fantastic opportunity for an established scientist to enter into an exciting innovative company. This is a great chance for this scientist to take this company’s pipeline from preclinical into the clinic by the end of 2017.
This opportunity has understandably been incredibly popular. We encourage all interested candidates to apply without delay as it is likely that recruitment will close prematurely. Please direct all questions (if necessary) to “Chris” at email@example.com cswain (at) barringtonjames (dot) com alongside a copy of your CV.
Posted by Chris Swain Team Sales Manager
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.